Skip to main content

Cardiff Oncology, Inc.

CRDF
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001213037

In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Cardiff Oncology, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of CRDF: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders9487−7
Shares21.1M22.0M+899.5K (+4.3%)
Value$140.7M$132.1M−$8.65M (−6.1%)

New holders (14)

Institutions that held Cardiff Oncology, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to CRDF in Q4 2021
InstitutionSharesValue% of portfolio
Point72 Asset Management, L.P.501,649$3.02M0.01%
Chartwell Investment Partners, LLC77,607$466.0K0.01%
Anson Funds Management LP69,381$417.0K0.06%
Squarepoint Ops LLC20,972$126.0K0.00%
Price T Rowe Associates Inc20,680$124.0K0.00%
Jane Street Group, LLC18,495$111.0K0.00%
Walleye Trading LLC16,298$98.0K0.00%
Gsa Capital Partners LLP15,512$93.0K0.01%
Aquatic Capital Management LLC8,000$48.0K0.09%
The PNC Financial Services Group, Inc.3,000$18.0K0.00%
Larson Financial Group LLC150$1.00K0.00%
Toronto Dominion Bank4$00.00%
Rockefeller Capital Management L.P.6$00.00%
Spire Wealth Management1,000––

Sold out (21)

Institutions that held Cardiff Oncology, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.